Integration of the anti-EGFR agent Panitumumab into clinical practice in metastatic colorectal cancer

Clinical Advances in Hematology and Oncology

Volumn 5, Issue 8, 2007, Pages 611-613

  Van Cutsem, Eric ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIREGULIN; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; K RAS PROTEIN; MATUZUMAB; OXALIPLATIN; PANITUMUMAB; PLATINUM COMPLEX; UNCLASSIFIED DRUG; VECTIBIX;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER RADIOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; HYPOMAGNESEMIA; IMMUNOHISTOCHEMISTRY; METASTASIS; PREDICTION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 34848821241     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Van Cutsem E, Peeters M, Siena S. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658-1664.
2. Naret CL, Ramalingam S, Beattie L, et al. Total blockade of the epidermal growth factor receptor with the combination of cetuximab and gefitinib: a phase I study for patients with recurrent non-small cell lung cancer (NSCLC). J Clin Oncol. 2006;24(18S pt 1).
3. Hecht R, Chidiac T, Mitchell E et al. An interim analysis of efficacy and safety from a randomized controlled trial of panitumumab with chemotherapy plus bevacizumab in metastatic colorectal cancer. Ann Oncol. 2007:18(S7).
4. Van Cutsem E, Peeters M, Gelderblom H et al. Cetuximab, dose-escalation in MCRC patients with no or slight skin reactions on standard treatment (Everest). Ann Oncol. 2007:18(S7).
5. Tejpar S, Peeters M, Humbler Y, et al. Dose-escalation study using up to twice the standard dose of cetuximab, in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab, standard dose treatment (EVEREST study): preliminary data. J Clin Oncol. 2006;24(18S pt 1).
6. Berlin J, Posey J, Tchekmedyian S, et al. Panimmumab with irinotecan/ leucovorin/5-fluorouracit for first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer. 2007;6:427-432.